Daniel Jones

The Ohio State University Wexner Medical Center — United States

Medicine · Health Sciences

9h-index522citations14works29.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(10), Animal Virus Infections Studies(4), COVID-19 Clinical Research Studies(3), Bacillus and Francisella bacterial research(3), Lung Cancer Treatments and Mutations(2)

Publications14 total

Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability
Journal of Virology·2025· 15 citedOpen Access
Immune Evasion, Cell-Cell Fusion, and Spike Stability of the SARS-CoV-2 XEC Variant: Role of Glycosylation Mutations at the N-terminal Domain
2024· 13 citedOpen Access
Abstract 4145068: Machine learning analysis of serum proteome in the diagnosis of COVID-19 myocarditis
Circulation·2024
Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib
Blood·2024· 38 citedOpen Access
Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion
mBio·2024· 43 citedOpen Access
CRE24-044: Response to Dabrafenib and Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Metastatic Non–Small Cell Lung Cancer
Journal of the National Comprehensive Cancer Network·2024
Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non–Small Cell Lung Cancer
Journal of the National Comprehensive Cancer Network·2024· 2 citedOpen Access
Distinct Patterns of SARS-CoV-2 BA.2.87.1 and JN.1 Variants in Immune Evasion, Antigenicity and Cell-Cell Fusion
2024· 7 citedOpen Access
Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants
Cell·2024· 149 citedOpen Access
Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3
Emerging Microbes & Infections·2023· 84 citedOpen Access
Continued evasion of neutralizing antibody response by Omicron XBB.1.16
Cell Reports·2023· 26 citedOpen Access
Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants
2023· 48 citedOpen Access
Immune Evasion and Membrane Fusion of SARS-CoV-2 XBB Subvariants EG.5.1 and XBB.2.3
2023· 9 citedOpen Access
Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2
2022· 87 citedOpen Access

Frequent Co-authors

Eugene M. Oltz(11), Richard J. Gumina(11), Shan‐Lu Liu(11), Julia N. Faraone(10), Yi-Min Zheng(10), Claire Carlin(10), Linda J. Saif(10), Kai Xu(7), Panke Qu(6), Joseph S. Bednash(6), Jeffrey C. Horowitz(6), Rama K. Mallampalli(5), Negin Goodarzi(4), Pei Li(4), Yajie Liu(4), Cheng Chih Hsu(4), Michelle Chamblee(4), Jiànróng Lǐ(4), Gerard Lozanski(2), Ashish R. Panchal(2)